Arta Dreimane

948 total citations
17 papers, 347 citations indexed

About

Arta Dreimane is a scholar working on Genetics, Hematology and Rheumatology. According to data from OpenAlex, Arta Dreimane has authored 17 papers receiving a total of 347 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Genetics, 15 papers in Hematology and 8 papers in Rheumatology. Recurrent topics in Arta Dreimane's work include Chronic Myeloid Leukemia Treatments (14 papers), Chronic Lymphocytic Leukemia Research (12 papers) and Eosinophilic Disorders and Syndromes (8 papers). Arta Dreimane is often cited by papers focused on Chronic Myeloid Leukemia Treatments (14 papers), Chronic Lymphocytic Leukemia Research (12 papers) and Eosinophilic Disorders and Syndromes (8 papers). Arta Dreimane collaborates with scholars based in Sweden, Finland and Norway. Arta Dreimane's co-authors include Martin Höglund, Leif Stenke, Johan Richter, Berit Markevärn, Ulla Olsson‐Strömberg, Fredrik Sandin, Anders Själander, Hans Wadenvik, Magnus Björkholm and Per Ljungman and has published in prestigious journals such as Blood, Journal of Neurology Neurosurgery & Psychiatry and British Journal of Haematology.

In The Last Decade

Arta Dreimane

17 papers receiving 340 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Arta Dreimane Sweden 9 296 246 123 74 50 17 347
Hyacinthe Johnson‐Ansah France 9 353 1.2× 293 1.2× 161 1.3× 90 1.2× 31 0.6× 18 414
Véronique Bédoucha Switzerland 5 327 1.1× 271 1.1× 163 1.3× 79 1.1× 36 0.7× 13 349
Lotta Ohm Sweden 8 355 1.2× 283 1.2× 147 1.2× 87 1.2× 75 1.5× 10 424
Juan Julio Kassack Ipiña Mexico 4 418 1.4× 366 1.5× 210 1.7× 81 1.1× 53 1.1× 5 471
Nelma Cristina D. Clementino Brazil 8 293 1.0× 231 0.9× 132 1.1× 68 0.9× 39 0.8× 16 312
María Soledad Undurraga Chile 4 425 1.4× 361 1.5× 212 1.7× 71 1.0× 47 0.9× 9 460
Stuart Phillis Australia 5 258 0.9× 223 0.9× 126 1.0× 52 0.7× 24 0.5× 6 295
Armin Leitner Germany 7 342 1.2× 303 1.2× 210 1.7× 105 1.4× 28 0.6× 13 451
Dushyant Verma United States 10 415 1.4× 289 1.2× 112 0.9× 51 0.7× 75 1.5× 14 486
Greg Malnassy United States 6 143 0.5× 118 0.5× 75 0.6× 73 1.0× 63 1.3× 10 254

Countries citing papers authored by Arta Dreimane

Since Specialization
Citations

This map shows the geographic impact of Arta Dreimane's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Arta Dreimane with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Arta Dreimane more than expected).

Fields of papers citing papers by Arta Dreimane

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Arta Dreimane. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Arta Dreimane. The network helps show where Arta Dreimane may publish in the future.

Co-authorship network of co-authors of Arta Dreimane

This figure shows the co-authorship network connecting the top 25 collaborators of Arta Dreimane. A scholar is included among the top collaborators of Arta Dreimane based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Arta Dreimane. Arta Dreimane is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

17 of 17 papers shown
1.
2.
Ljungman, Per, Adjmal Nahimi, Arta Dreimane, et al.. (2023). Haematopoietic stem cell transplantation for treatment of relapsing-remitting multiple sclerosis in Sweden: an observational cohort study. Journal of Neurology Neurosurgery & Psychiatry. 95(2). 125–133. 16 indexed citations
3.
Dahlén, Torsten, Gustaf Edgren, Per Ljungman, et al.. (2022). Adverse outcomes in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: Follow‐up of patients diagnosed 2002–2017 in a complete coverage and nationwide agnostic register study. American Journal of Hematology. 97(4). 421–430. 8 indexed citations
4.
Söderlund, Stina, Jesper Stentoft, Johan Richter, et al.. (2021). Long‐term tolerability and efficacy after initial PegIFN‐α addition to dasatinib in CML‐CP: Five‐year follow‐up of the NordCML007 study. European Journal Of Haematology. 107(6). 617–623. 5 indexed citations
5.
Hägglund, Hans, Akif Selim Yavuz, Arta Dreimane, et al.. (2020). Graft‐versus‐mastocytosis effect after donor lymphocyte infusion: Proof of principle. European Journal Of Haematology. 106(2). 290–293. 3 indexed citations
6.
Lübking, Anna, Arta Dreimane, Fredrik Sandin, et al.. (2019). Allogeneic stem cell transplantation for chronic myeloid leukemia in the TKI era: population-based data from the Swedish CML registry. Bone Marrow Transplantation. 54(11). 1764–1774. 25 indexed citations
7.
Tynngård, Nahreen, Niklas Boknäs, Marie Trinks, Arta Dreimane, & Gösta Berlin. (2018). Storage‐induced change in platelet transfusion response evaluated by serial transfusions from one donor to one patient. Transfusion. 59(2). 723–728. 3 indexed citations
8.
Landberg, Niklas, Arta Dreimane, Marianne Rissler, Rolf Billström, & Helena Ågerstam. (2017). Primary cells in BCR/FGFR1‐positive 8p11 myeloproliferative syndrome are sensitive to dovitinib, ponatinib, and dasatinib. European Journal Of Haematology. 99(5). 442–448. 15 indexed citations
9.
Hjorth‐Hansen, Henrik, Jesper Stentoft, Johan Richter, et al.. (2016). Safety and efficacy of the combination of pegylated interferon-α2b and dasatinib in newly diagnosed chronic-phase chronic myeloid leukemia patients. Leukemia. 30(9). 1853–1860. 49 indexed citations
10.
Höglund, Martin, Leif Stenke, Solveig Wållberg‐Jonsson, et al.. (2016). Increased prevalence of prior malignancies and autoimmune diseases in patients diagnosed with chronic myeloid leukemia. Leukemia. 30(7). 1562–1567. 17 indexed citations
11.
Söderlund, Stina, Torsten Dahlén, Fredrik Sandin, et al.. (2016). Advanced phase chronic myeloid leukaemia (CML) in the tyrosine kinase inhibitor era – a report from the Swedish CML register. European Journal Of Haematology. 98(1). 57–66. 7 indexed citations
12.
Höglund, Martin, Leif Stenke, Solveig Wållberg Jonsson, et al.. (2015). Increased Prevalence of Prior Malignancies and Autoimmune Diseases in Patients Diagnosed with Chronic Myeloid Leukemia. Blood. 126(23). 1586–1586. 2 indexed citations
13.
Stenke, Leif, Martin Höglund, Fredrik Sandin, et al.. (2015). Second malignancies following treatment of chronic myeloid leukaemia in the tyrosine kinase inhibitor era. British Journal of Haematology. 169(5). 683–688. 43 indexed citations
14.
Hjorth‐Hansen, Henrik, Jesper Stentoft, Johan Richter, et al.. (2015). Safety and Efficacy of Addition of Pegylated Interferon alpha2b to Standard Dose Dasatinib in Newly Diagnosed Chronic Phase CML Patients. Blood. 126(23). 477–477. 8 indexed citations
15.
Höglund, Martin, Fredrik Sandin, Magnus Björkholm, et al.. (2014). Second Malignancies Following Treatment of Chronic Myeloid Leukemia in the Tyrosine Kinase Inhibitor Era. Blood. 124(21). 154–154. 3 indexed citations
16.
Hjorth‐Hansen, Henrik, Leif Stenke, Stina Söderlund, et al.. (2014). Dasatinib induces fast and deep responses in newly diagnosed chronic myeloid leukaemia patients in chronic phase: clinical results from a randomised phase‐2 study (NordCML006). European Journal Of Haematology. 94(3). 243–250. 54 indexed citations
17.
Höglund, Martin, Fredrik Sandin, Karin Hellström, et al.. (2013). Tyrosine kinase inhibitor usage, treatment outcome, and prognostic scores in CML: report from the population-based Swedish CML registry. Blood. 122(7). 1284–1292. 83 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Hyacinthe Johnson‐Ansah Breakdown of academic impact, for papers by Véronique Bédoucha Breakdown of academic impact, for papers by Lotta Ohm Breakdown of academic impact, for papers by Juan Julio Kassack Ipiña Breakdown of academic impact, for papers by Nelma Cristina D. Clementino Breakdown of academic impact, for papers by María Soledad Undurraga Breakdown of academic impact, for papers by Stuart Phillis Breakdown of academic impact, for papers by Armin Leitner Breakdown of academic impact, for papers by Dushyant Verma Breakdown of academic impact, for papers by Greg Malnassy
Rankless by CCL
2026